臨床整形外科49巻3号

2014年03月発行

誌上シンポジウム 良性腫瘍に対する最新の治療戦略

デスモイド

著者： 河野博隆¹ 篠田裕介¹

所属機関： ¹東京大学医学部附属病院整形外科

ページ範囲：P.215 - P.219

　デスモイドは強い局所浸潤性を示す中間群の間葉系腫瘍である．治療法として悪性腫瘍と同様の広範切除が標準とされてきたが，高い局所再発率が問題となっていた．その後，病態の解明が進み，治療法の概念に大きな変化が生じている．薬物療法，放射線療法を含むさまざまな治療法が試みられ，治療法の選択肢は広がったが，依然として「標準的」な治療法が確立したとは言えない．本稿では，これまでにわかったデスモイドの病態，各種治療方法の成績を概観し，デスモイドに対する現状の治療戦略と今後の展望について概説する．

参考文献

1) Bowley E, O'Gorman DB, Gan BS:Beta-catenin signaling in fibroproliferative disease. J Surg Res 138:141-150, 2007

2) Chugh R, Wathen JK, Patel SR, et al:Efficacy of imatinib in aggressive fibromatosis:Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res 16:4884-4891, 2010

3) de Camargo VP, Keohan ML, D'Adamo DR, et al:Clinical outcomes of systemic therapy for patients with deep fibromatosis (desmoid tumor). Cancer 116:2258-2265, 2010

4) Fletcher JA, Bridge JA, Hogendoom PCW, et al:Desmoid-type fibromatosis. WHO Classification of Tumours of Soft Tissue and Bone. Lyon:IARC Press, pp.72-73, 2013

5) Guadagnolo BA, Zagars GK, Ballo MT:Long-term outcomes for desmoid tumors treated with radiation therapy. Int J Radiat Oncol Biol Phys 71:441-447, 2008

6) Gounder MM, Lefkowitz RA, Keohan ML, et al:Activity of Sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res 17:4082-4090, 2011

7) Gronchi A, Casali PG, Mariani L, et al:Quality of surgery and outcome in extra-abdominal aggressive fibromatosis:a series of patients surgically treated at a single institution. J Clin Oncol 21:1390-1397, 2003

8) Gronchi A, Colombo C, Le Péchoux C, et al:Sporadic desmoid-type fibromatosis:a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group. Ann Oncol. 2013 Dec 9．［Epub ahead of print］

9) Huang K, Wang CM, Chen JG, et al:Prognostic factors influencing event-free survival and treatments in desmoid-type fibromatosis:analysis from a large institution. Am J Surg 2013 Oct 9．pii:S0002-9610(13)00447-9.

10) Janinis J, Patriki M, Vini L, et al:The pharmacological treatment of aggressive fibromatosis:a systematic review. Ann Oncol 14:181-190, 2003

11) Keus RB, Nout RA, Blay JY, et al:Results of a phase II pilot study of moderate dose radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study (EORTC 62991-22998). Ann Oncol 24:2672-2676, 2013

12) Lazar AJ, Tuvin D, Hajibashi S, et al:Specific mutations in the beta-catenin gene (CTNNB1) correlate with local recurrence in sporadic desmoid tumors. Am J Pathol 173:1518-1527, 2008

13) Li M, Cordon-Cardo C, Gerald WL, et al:Desmoid fibromatosis is a clonal process. Hum Pathol 27:939-943, 1996

14) Martin-Liberal J, Benson C, McCarty H, et al:Pazopanib is an active treatment in desmoid tumour/aggressive fibromatosis. Clin Sarcoma Res 3:13, 2013

15) Nakayama T, Tsuboyama T, Toguchida J, et al:Natural course of desmoid-type fibromatosis. J Orthop Sci 13:51-55, 2008

16) Nishida Y, Tsukushi S, Shido Y, et al:Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors:a pilot study. J Clin Oncol 28, e107-109, 2010

17) Nieuwenhuis MH, Casparie M, Mathus-Vliegen LM, et al:A nation-wide study comparing sporadic and familial adenomatous polyposis-related desmoid-type fibromatoses. Int J Cancer 129:256-261, 2011

18) Nuyttens JJ, Rust PF, Thomas CR Jr, et al:Surgery versus radiation therapy for patients with aggressive fibromatosis or desmoid tumors:A comparative review of 22 articles. Cancer 88:1517-1523, 2000

19) Okuno S:The enigma of desmoid tumors. Curr Treat Options Oncol 7:438-443, 2006

20) Salas S, Dufresne A, Bui B, et al:Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors:a wait-and-see policy according to tumor presentation. J Clin Oncol 29:3553-3558, 2011

21) Sinha A, Tekkis PP, Gibbons DC, et al:Risk factors predicting desmoid occurrence in patients with familial adenomatous polyposis:a meta-analysis. Colorectal Dis 13:1222-1229, 2011